Journal Article

DKFZ-2026-02175

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Wesener, M. C. ; Demel, U. M. ; Pabst, T. ; Teipel, R. ; Albici, A.-M. ; Von Tresckow, B. ; Teichert, M. ; Boquoi, A. ; Holderried, T. ; Schmitz, F. ; Müller, F. ; Rößiger, F.-L. ; Hoffmann, M. ; Schub, N. ; Tovar, N. ; Oliver-Caldes, A. ; Kröger, N. ; Baermann, B.-N. ; Bohl, S. ; Fandrei, D. ; Vucinic, V. ; Strassl, I. ; Stölzel, F. ; De Larrea, C. F. ; Keller, U.DKFZ* ; Busse, A.DKFZ* ; Merz, M. ; Gagelmann, N.

2026
Ferrata Storti Foundation Pavia

Abstract: Disease burden at the time of BCMA-directed chimeric antigen receptor (CAR) T-cell infusion is a key determinant of outcome in relapsed or refractory multiple myeloma (RRMM). Bridging therapy is frequently administered between leukapheresis and infusion to prevent disease progression, yet its clinical impact remains unclear. We conducted a multicenter real-world cohort study of 399 patients with RRMM treated with BCMA-directed CAR T-cell therapy, including 348 (87%) who received bridging therapy. Bridging therapy recipients had more advanced and biologically adverse disease, including higher rates of high-risk cytogenetics and penta-class refractoriness. Bridging efficacy varied substantially by regimen (P.

Note: #DKTKZFB9# / #NCTZFB9# / epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Berlin (BE01)
2. Koordinierungsstelle NCT Berlin (BR01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---